Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis.
15,000 Cases Found: Which Drugs Harm Your Lungs?
A retrospective pharmacovigilance investigation analyzed 15,374 cases in FAERS and Vigibase databases to identify drug-induced eosinophilic …
A massive data review reveals which medicines might silently damage your lungs.
Savolitinib and durvalumab combination yields response rates of 34% to 53% in papillary renal cancer patients.
New Hope for a Tough Kidney Cancer Type
This single-arm phase II study evaluated savolitinib and durvalumab in 41 treatment-naïve or pretreated patients with papillary renal cancer…
A new drug pair breaks the shield blocking treatment for a rare kidney cancer type, offering patients a chance at longer survival after stan…
Salvage radiotherapy for limited metastatic relapse in small cell lung cancer after durvalumab.
Two patients with limited-stage small cell lung cancer had durable disease control after salvage radiotherapy and immunotherapy
This case report describes two patients with limited-stage small cell lung cancer who developed limited metastatic relapse after chemoradiot…
Two limited-stage small cell lung cancer patients stayed stable for over four years after targeted radiation and continued immunotherapy.
Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone.
New treatment approach improves survival for advanced bladder cancer patients before surgery
This randomized, phase III, open-label trial evaluated neoadjuvant and adjuvant durvalumab combined with gemcitabine and cisplatin versus ge…
Adding an immune drug to standard chemotherapy before bladder surgery helps patients stay cancer-free longer and live longer than older trea…
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide.
Two Cancer Drugs Teamed Up — Who Actually Benefits Most?
This single-arm, open-label phase 2 trial evaluated olaparib plus durvalumab in 60 men with metastatic castration-resistant prostate cancer …
A new prostate cancer drug combo helped men with specific DNA repair gene variants live more than twice as long without their cancer progres…
Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers
New standards of care established for bladder, kidney, prostate, testicular, and penile cancers in 2025.
A systematic review and meta-analysis of 40 phase II/III RCTs in patients with bladder, kidney, prostate, testicular, and penile cancers fou…
New 2025 standards of care for bladder, kidney, prostate, testicular, and penile cancers now emphasize biomarker-driven strategies and immun…
Durvalumab plus chemotherapy shows 35% response in phase II trial for metastatic pulmonary sarcomatoid carcinoma
Small study tests drug combination for rare, aggressive lung cancer
A phase II single-arm trial in 20 patients with recurrent/metastatic pulmonary sarcomatoid carcinoma evaluated durvalumab plus doxorubicin/i…
A rare lung cancer drug combo shrank tumors in 35% of patients, offering hope for those with this aggressive disease despite common side eff…